Edition:
United States

CSL Ltd (CSL.AX)

CSL.AX on Australia Stock Exchange

126.79AUD
21 Jul 2017
Change (% chg)

$-0.60 (-0.47%)
Prev Close
$127.39
Open
$126.85
Day's High
$129.08
Day's Low
$125.16
Volume
1,396,394
Avg. Vol
957,548
52-wk High
$145.00
52-wk Low
$91.62

CSL.AX

Chart for CSL.AX

About

CSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment... (more)

Overall

Beta: 0.86
Market Cap(Mil.): $57,703.05
Shares Outstanding(Mil.): 452.96
Dividend: 0.84
Yield (%): 1.35

Financials

  CSL.AX Industry Sector
P/E (TTM): 34.94 11.87 15.95
EPS (TTM): 3.65 -- --
ROI: 20.17 -9.97 -8.24
ROE: 46.20 -9.81 -7.87

BRIEF-CSL Ltd responds to patent infringement complaint

* has become aware that Bioverativ has filed complaints in U.S. District Court for district of Delaware

Jul 09 2017

Australia shares extend losses as CSL, Fairfax slide; NZ edge lower

July 3 Australian shares extended losses from the end of last week, with Monday's weakness led by biotech giant CSL Ltd, the biggest drag on the benchmark, while Fairfax Media tumbled after two private equity firms withdrew rival takeover bids.

Jul 03 2017

BRIEF-CSL to acquire majority stake in chinese plasma fractionator Wuhan Zhong Yuan Rui De Biologicals Products

* CSL to acquire majority stake in chinese plasma fractionator Wuhan Zhong Yuan Rui De Biologicals Products Source text for Eikon: Further company coverage:

Jun 12 2017

Australian, NZ stocks finish modestly higher

May 24 Australian shares pared early gains to end marginally higher on Wednesday, underpinned by industrial and consumer stocks.

May 24 2017

BRIEF-Momenta Pharmaceuticals announces HSR clearance

* Momenta Pharmaceuticals announces Hart-Scott-Rodino clearance for collaboration and license agreement with CSL

Feb 17 2017

BRIEF-CSL Ltd updates on outlook

* "Group's net profit after tax (NPAT) is expected to grow in range of approximately 18 to 20% at constant currency"

Feb 14 2017

Earnings vs. Estimates